TARA vs. GNLX

In the year-to-date period, TARA achieves a -39.02% return, which is significantly lower than GNLX's 5.08% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Protara Therapeutics, Inc. (TARA) and Genelux Corporation (GNLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current TARA Sharpe Ratio is -0.01, which is higher than the GNLX Sharpe Ratio of -0.27. The chart below compares the historical Sharpe Ratios of TARA and GNLX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither TARA nor GNLX has paid dividends to shareholders.

The maximum TARA drawdown since its inception was -99.86%, roughly equal to the maximum GNLX drawdown of -95.74%. Use the drawdown chart below to compare losses from any high point for TARA and GNLX. For additional features, visit the drawdowns tool.

The current volatility for Protara Therapeutics, Inc. (TARA) is 25.49%, while Genelux Corporation (GNLX) has a volatility of 35.22%. This indicates that TARA experiences smaller price fluctuations and is considered to be less risky than GNLX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Protara Therapeutics, Inc. and Genelux Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.